SNA011

SNA011 is a preclinical-stage radiopharmaceutical diagnostic imaging agent developed by SmartNuclide (Suzhou SmartNuclide Biopharmaceutical). Utilizing the company's proprietary single-domain antibody (nanobody) platform, SNA011 is engineered to target the thyroid-stimulating hormone (TSH) receptor, which is expressed in certain solid tumors. As a diagnostic tracer, it is intended to facilitate the visualization and staging of tumors through nuclear medicine imaging techniques such as PET or SPECT. The use of a nanobody-based modality aims to provide high binding affinity and rapid systemic clearance, potentially improving the signal-to-noise ratio for clearer diagnostic results compared to traditional antibody-based tracers.